Natera Director Chapman Rowan E sells 2750 shares at $166.99 on 2025-08-28.

Natera, Inc. [NTRA] has announced that Director Chapman Rowan E has executed a transaction involving the sale of 2,750 shares at a price of $166.99 per share on August 28, 2025.

Title: Natera, Inc. [NTRA] Director Executes Share Sale

Natera, Inc. [NTRA], a leading developer of liquid biopsy tests, has seen a significant transaction involving its Director, Chapman Rowan E. On August 28, 2025, Rowan sold 2,750 shares of the company's common stock at a price of $166.99 per share [3]. This transaction, filed under SEC Form 4, provides insight into the company's insider trading activities and market sentiment.

The sale of 2,750 shares by Rowan, who holds a 10% ownership stake in the company, reflects the latest in a series of transactions by Natera's insiders. The total number of shares Rowan owns, as of the latest filing, stands at 8,616, indicating a reduction in his holding following the August 28 sale [3].

Natera has been making strides in the liquid biopsy market, with recent positive clinical trial results for its Signatera test in muscle-invasive bladder cancer (MIBC). The company's stock has shown strong momentum, with a 30% return over the past year and a current trading price of $161.94 [2]. Analysts maintain a strong buy consensus with price targets ranging from $37 to $255, reflecting the market's optimism about the company's prospects [2].

The liquid biopsy market is anticipated to surge, with an estimated market value of USD 7.05 billion by 2030, growing from USD 4.03 billion in 2025 at a CAGR of 11.8% [1]. The market's growth is driven by the increasing burden of cancer, cancer awareness initiatives, and the expanding benefits of liquid biopsy over traditional biopsy procedures [1].

Natera's recent earnings report for the second quarter of 2025 showed significant revenue growth of 44% year-over-year, albeit with a shortfall in earnings per share (EPS) [2]. The company's strong clinical and financial performance has led several analyst firms to adjust their price targets, with RBC Capital raising its target to $255, Bernstein SocGen to $205, and TD Cowen to $215 [2].

As Natera continues to build its clinical evidence and secure regulatory approvals, investors will be closely watching the company's progress in the liquid biopsy market. The recent share sale by Rowan provides a snapshot of the insider's market sentiment and underscores the ongoing interest in Natera's growth prospects.

References

[1] https://www.globenewswire.com/news-release/2025/09/02/3142413/28124/en/Liquid-Biopsy-Market-Trends-and-Industry-Forecast-to-2030-Featuring-Strategic-Analysis-of-Natera-Guardant-Health-Myriad-Genetics-Illumina-and-Roche-Among-Others.html
[2] https://in.investing.com/news/analyst-ratings/natera-stock-rises-on-positive-bladder-cancer-trial-results-ubs-reiterates-buy-93CH-4971797
[3] https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-fb421d95e4b7.html